Analysts Set Maze Therapeutics, Inc. (NASDAQ:MAZE) Price Target at $41.88

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) have earned a consensus rating of “Buy” from the eleven research firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, eight have assigned a buy rating and two have issued a strong buy rating on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $41.8750.

A number of research analysts have recently issued reports on MAZE shares. Wall Street Zen downgraded Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Guggenheim lifted their target price on Maze Therapeutics from $19.00 to $34.00 and gave the company a “buy” rating in a research note on Monday, September 15th. HC Wainwright boosted their target price on shares of Maze Therapeutics from $50.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday. Wedbush raised their price target on shares of Maze Therapeutics from $35.00 to $36.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Finally, BTIG Research lifted their price objective on shares of Maze Therapeutics from $30.00 to $37.00 and gave the stock a “buy” rating in a research report on Friday, September 12th.

Maze Therapeutics Stock Performance

Shares of MAZE opened at $41.71 on Friday. The company has a 50 day moving average price of $31.96 and a 200-day moving average price of $21.05. Maze Therapeutics has a fifty-two week low of $6.71 and a fifty-two week high of $43.29. The stock has a market capitalization of $2.01 billion and a PE ratio of -2.00.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.66) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.08.

Insider Transactions at Maze Therapeutics

In other news, Director Richard H. Scheller sold 20,744 shares of the company’s stock in a transaction on Monday, September 15th. The stock was sold at an average price of $22.37, for a total transaction of $464,043.28. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. CWM LLC acquired a new position in Maze Therapeutics during the 2nd quarter valued at about $28,000. Ameritas Investment Partners Inc. increased its holdings in shares of Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after acquiring an additional 738 shares in the last quarter. Corebridge Financial Inc. acquired a new position in shares of Maze Therapeutics during the first quarter valued at about $48,000. Russell Investments Group Ltd. raised its position in shares of Maze Therapeutics by 947.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after purchasing an additional 1,725 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in Maze Therapeutics in the 3rd quarter worth approximately $52,000.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.